retatrutide triple agonist phase 2 obesity trial just posted its first 3 win — and the numbers are big. 🧬 In the 68-week TRIUMPH-4 (445 adults with + knee osteoarthritis), Eli Lilly's triple-agonist peptide — UAE Variant:5mg GLP-1 receptor agonists are

retatrutide triple agonist phase 2 obesity trial just posted its first 3 win — and the numbers are big. 🧬 In the 68-week TRIUMPH-4 (445 adults with + knee osteoarthritis), Eli Lilly's triple-agonist peptide — UAE Variant:5mg GLP-1 receptor agonists are

GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal.

J Clin Med 2024;13:6

UAE

Variant:5mg

The only circumstances where compounding semaglutide or tirzepatide may be permissible are: True allergy to a specific inactive ingredient in the FDA-approved version, documented with allergy testing and medical records Documented medical need for a different concentration not commercially available, with clear clinical justification Specific patient population requiring dosage form modification , such as pediatric use, with proper medical justification Healthcare providers must document medical necessity with extensive clinical evidence